ES2422263T3 - Pirazoles bicíclicos como inhibidores de la proteinquinasa - Google Patents

Pirazoles bicíclicos como inhibidores de la proteinquinasa

Info

Publication number
ES2422263T3
ES2422263T3 ES09775222T ES09775222T ES2422263T3 ES 2422263 T3 ES2422263 T3 ES 2422263T3 ES 09775222 T ES09775222 T ES 09775222T ES 09775222 T ES09775222 T ES 09775222T ES 2422263 T3 ES2422263 T3 ES 2422263T3
Authority
ES
Spain
Prior art keywords
alkyl
heteroaryl
optionally substituted
group selected
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09775222T
Other languages
English (en)
Inventor
Maurizio Pulici
Chiara Marchionni
Claudia Piutti
Fabio Gasparri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Application granted granted Critical
Publication of ES2422263T3 publication Critical patent/ES2422263T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (I):**Fórmula** en donde: X es CH o N; R1 es hidrógeno, halógeno, NR7R8, NHCOR9, SR10 o SO2R, en donde: R7 y R8 son, independientemente uno de otro, hidrógeno, o un grupo opcionalmentesustituido seleccionado entre alquilo (C1-C8) alquilo lineal o ramificado, cicloalquilo (C3-C8), heterociclilo, arilo y heteroarilo, o R7 y R8 tomados juntos pueden formar un grupoftalilo, R9 es OR10, NR11R12 o un grupo opcionalmente sustituido seleccionado de alquilo (C1-C8) alquilo lineal o ramificado, alquenilo (C2-C8) o alquenilo (C2-C8), cicloalquilo (C3-C8),heterociclilo, arilo y heteroarilo, R10 es un grupo opcionalmente sustituido seleccionado entre alquilo (C1-C8) lineal oramificado, cicloalquilo (C3-C8), heterociclilo, arilo y heteroarilo, R11 y R12 son, independientemente uno de otro, hidrógeno o un grupo opcionalmentesustituido seleccionado de alquilo (C1-C8) lineal o ramificado, cicloalquilo (C3-C8),heterociclilo, arilo y heteroarilo, o tomados junto con el átomo de nitrógeno al cual estánunidos R11 y R12 pueden formar un heterociclilo o heteroarilo de 3 a 8 miembrosopcionalmente sustituido, que contiene opcionalmente un heteroátomo o grupoheteroatómico adicional seleccionado entre S, O, N o NH.
ES09775222T 2008-12-19 2009-12-17 Pirazoles bicíclicos como inhibidores de la proteinquinasa Active ES2422263T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172429 2008-12-19
PCT/EP2009/067438 WO2010070060A1 (en) 2008-12-19 2009-12-17 Bicyclic pyrazoles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2422263T3 true ES2422263T3 (es) 2013-09-10

Family

ID=41565939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09775222T Active ES2422263T3 (es) 2008-12-19 2009-12-17 Pirazoles bicíclicos como inhibidores de la proteinquinasa

Country Status (5)

Country Link
US (1) US8524707B2 (es)
EP (1) EP2373664B1 (es)
JP (1) JP5490137B2 (es)
ES (1) ES2422263T3 (es)
WO (1) WO2010070060A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2402339A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
WO2012177782A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
JP6042896B2 (ja) * 2011-10-06 2016-12-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としての複素環ピリ（ミ）ジニルピラゾール
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
KR102091295B1 (ko) 2011-11-23 2020-03-19 어레이 바이오파마 인크. 제약 제제
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN106883266B (zh) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体
EP4281182A1 (en) * 2021-01-22 2023-11-29 Hibercell, Inc. Gcn2 modulating compounds and uses thereof
WO2023091873A1 (en) * 2021-11-19 2023-05-25 The Board Of Trustees Of The University Of Illinois Gram-negative specific antibiotics sparing effect on gut microbiome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD103006A1 (es) 1972-12-29 1974-01-05
DD157803A1 (de) 1980-03-20 1982-12-08 Klaus Peseke Verfahren zur herstellung von pyrazolo[5.1-b][1.3]thiazinen
JPS6438091A (en) * 1986-03-20 1989-02-08 Takeda Chemical Industries Ltd Condensed heterocyclic sulfonylurea
WO1993015074A1 (en) 1992-01-29 1993-08-05 E.I. Du Pont De Nemours And Company Substituted phenylheterocyclic herbicides
WO2002012250A2 (en) 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004529119A (ja) * 2001-03-08 2004-09-24 スミスクライン ビーチャム コーポレーション ピラゾロピリジン誘導体
ES2289116T3 (es) * 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
ATE430747T1 (de) * 2004-12-21 2009-05-15 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
CA2630079A1 (en) * 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
FR2904626B1 (fr) * 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US8524707B2 (en) 2013-09-03
JP2012512837A (ja) 2012-06-07
EP2373664B1 (en) 2013-06-12
US20110257165A1 (en) 2011-10-20
WO2010070060A1 (en) 2010-06-24
EP2373664A1 (en) 2011-10-12
JP5490137B2 (ja) 2014-05-14

Similar Documents

Publication Publication Date Title
ES2422263T3 (es) Pirazoles bicíclicos como inhibidores de la proteinquinasa
CO6300866A2 (es) Derivado de imidazopiridin - 2 - on
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR058404A1 (es) Derivados diamina como inhibidores de leucotrieno a4 hidrolasa
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
ES2590504T3 (es) N-ciclilamidas como nematicidas
BR112012018412A2 (pt) isoquinolinonas e quinazolinonas substituídas
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
CO6220966A2 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
AR067838A1 (es) Compuestos pirrolicos, composiciones farmaceuticas que los contienen y usos
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
CY1114067T1 (el) Παραγωγα πυρρολιδιν-2-ονης ως ρυθμιστες υποδοχεα ανδρογονων
PE20090905A1 (es) Compuestos heterociclicos de amidas como inhibidores de la proteincinasa
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP11010912A (es) Compuestos de pirrol
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
CO5700818A2 (es) Derivados de oxazol de tetraciclina
ECSP055987A (es) Derivados de heteroarilcarbamoilbenceno
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos